Cargando…

Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials

As an immunomodulatory agent with antitumor activity, lenalidomide has been evaluated for its value in diffuse large B-cell lymphoma (DLBCL). We performed a meta-analysis to gain a better understanding of the efficacy and safety of lenalidomide in DLBCL. PubMed, Cochrane Library, and Embase were sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jia, Mi, Ruihua, Chen, Lin, Guo, Xiaoli, Liang, Taotao, Yin, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390621/ https://www.ncbi.nlm.nih.gov/pubmed/36315313 http://dx.doi.org/10.1007/s10238-022-00920-2

Ejemplares similares

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
por: Li, Jia, et al.
Publicado: (2021)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Lenalidomide in Diffuse Large B-Cell Lymphoma
por: Thieblemont, Catherine, et al.
Publicado: (2012)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
por: Palmieri, R., et al.
Publicado: (2019)

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
por: Desai, Madhav, et al.
Publicado: (2013)

Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment
por: Ma, Li-Yangxue, et al.
Publicado: (2018)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
por: Al Dhafiri, Mahdi, et al.
Publicado: (2019)

Real‐world data for lenalidomide maintenance in responding patients of diffuse large B‐cell lymphoma
por: Wang, Xiaoyan, et al.
Publicado: (2023)

Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy
por: Yin, Qingsong, et al.
Publicado: (2014)

PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Wei, X., et al.
Publicado: (2022)

JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide
por: Xu, Peng-Peng, et al.
Publicado: (2017)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis
por: Liu, Jia, et al.
Publicado: (2021)

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients with High/High-intermediate risk Diffuse Large B-Cell Lymphoma
por: Reddy, Nishitha M., et al.
Publicado: (2016)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma
por: Cencini, Emanuele, et al.
Publicado: (2017)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis
por: Al-Mansour, Mubarak, et al.
Publicado: (2020)

Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Qiao, Shu-Kai, et al.
Publicado: (2015)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report
por: Hu, Pan, et al.
Publicado: (2021)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
por: Cortés-Hernández, Josefina, et al.
Publicado: (2012)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma
por: Dührsen, Ulrich, et al.
Publicado: (2021)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wilson, Wyndham H., et al.
Publicado: (2021)

Lenalidomide-induced diffuse alveolar hemorrhage
por: Saheer, S., et al.
Publicado: (2014)

PB2112: MINDWAY: A PHASE IB/II DOSE OPTIMIZATION STUDY TO ASSESS SAFETY AND PHARMACOKINETICS OF TAFASITAMAB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Greil, R., et al.
Publicado: (2022)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Huilai, et al.
Publicado: (2023)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
por: Xie, Chun-Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4h3ue69o06ec0o1vl4tl331tq1